3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
39
Neoplasms
6
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Prostatic Neoplasms, Castration-Resistant
3
Metastatic Castration-Resistant Prostate Cancer
3
Colorectal Neoplasms
3
Urogenital Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Melanoma
2
Carcinoma, Hepatocellular
2
Bulbo-Spinal Atrophy, X-Linked
2
Bites and Stings
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumours
1
Prostatic Diseases
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer
1
Interventions
pembrolizumab
2
radium Ra 223 dichloride
1
enzalutamide
1
efineptakin alfa
1
abiraterone
1
Radium-223
1
Pluvicto
1
PSMA-11
1
Lutetium-177
1
Lutetium
1
Injections
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metastatic Castration-resistant Prostate Cancer (mCRPC)
×
abiraterone
×
Clear all
NCT03896984
2021-12-29
PHENIX
Bayer
Completed
346 enrolled